2seventy bio Crecimiento futuro

Future controles de criterios 1/6

2seventy bio se prevé un crecimiento anual de los beneficios y los ingresos de 58.8% y 0.2% respectivamente. Se prevé que el BPA sea de grow en 61.8% al año. Se prevé que la rentabilidad de los fondos propios sea de -8.6% en 3 años.

Información clave

70.9%

Tasa de crecimiento de los beneficios

72.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.1%
Tasa de crecimiento de los ingresos	8.4%
Rentabilidad financiera futura	-14.0%
Cobertura de analistas	Good
Última actualización	17 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

Aug 10

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:TSVT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	109	-19	N/A	N/A	5
12/31/2025	114	-33	N/A	106	8
12/31/2024	88	-98	N/A	8	8
12/31/2023	100	-218	-181	-167	N/A
9/30/2023	146	-184	-176	-160	N/A
6/30/2023	147	-180	-226	-199	N/A
3/31/2023	125	-215	-238	-213	N/A
12/31/2022	91	-254	-259	-228	N/A
9/30/2022	51	-292	-259	-238	N/A
6/30/2022	57	-284	-237	-221	N/A
3/31/2022	51	-291	-233	-216	N/A
12/31/2021	55	-292	-226	-207	N/A
9/30/2021	48	-308	-229	-203	N/A
6/30/2021	48	-320	-244	-223	N/A
3/31/2021	150	-222	-180	-157	N/A
12/31/2020	248	-120	-90	-68	N/A
12/31/2019	44	-321	-268	-208	N/A
12/31/2018	55	-200	-197	-146	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: TSVT se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: TSVT se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: TSVT se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: TSVTSe prevé que los ingresos de la empresa (8.6% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: TSVTSe prevé que los ingresos de la empresa (0.2% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: TSVT se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

2seventy bio Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 24%

Forecast to breakeven in 2025

Price target increased by 33% to US$10.67

2Seventy Bio, Inc. Does Not Expect to Achieve the Original Revenue Guidance for 2023

Consensus estimates of losses per share improve by 15%

Price target decreased by 11% to US$25.00

Recent updates

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

Consensus revenue estimates fall by 24%

New minor risk - Shareholder dilution

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.40 loss per share (vs US$1.76 loss in 3Q 2022)

Forecast to breakeven in 2025

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Price target increased by 33% to US$10.67

2seventy bio, Inc. Announces Executive and Board Changes

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

President recently sold US$280k worth of stock

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

High number of new and inexperienced directors

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2Seventy Bio, Inc. Does Not Expect to Achieve the Original Revenue Guidance for 2023

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces Resignation of Nick Leschly as CEO

President recently sold US$51k worth of stock

Consensus estimates of losses per share improve by 15%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President recently sold US$55k worth of stock

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target decreased by 11% to US$25.00

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 12%

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

President recently sold US$69k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

Chief Operating Officer recently sold US$108k worth of stock

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients

2seventy bio Prospects

Consensus revenue estimates fall by 16%

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3

President recently sold US$89k worth of stock

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

President recently sold US$75k worth of stock

Consensus revenue estimates fall by 13%

2Seventy Bio, Inc. Announces Resignation of William Sellers to Its Board of Directors

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus forecasts updated

2Seventy Bio, Inc. to Present New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, At the AACR Annual Meeting

Consensus forecasts updated